P

Inventor

BURNETT DUANE A

US62 patents
⚠️ This page may combine multiple inventors who share the name “BURNETT DUANE A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

SCHERING CORP

35 patents
USRE37721EMay 28, 2002

Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

SCHERING CORP99 citations99
US5846966ADec 8, 1998

Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors

SCHERING CORP171 citations99
US5656624AAug 12, 1997

4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents

SCHERING CORP115 citations97
US5744467AApr 28, 1998

Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents

SCHERING CORP77 citations96
US5698548ADec 16, 1997

Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents

SCHERING CORP88 citations96
US5688787ANov 18, 1997

Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof

SCHERING CORP90 citations96
US5633246AMay 27, 1997

Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents

SCHERING CORP91 citations96
US5624920AApr 29, 1997

Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents

SCHERING CORP88 citations96
US7208486B2Apr 24, 2007

Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

SCHERING CORP16 citations93
US6664273B2Dec 16, 2003

Piperidine based MCH antagonists for treatment of obesity and CNS disorders

SCHERING CORP45 citations92
US6632933B2Oct 14, 2003

Use of azetidinone compounds

SCHERING CORP18 citations90
USRE42461EJun 14, 2011

Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

SCHERING CORP7 citations84
US7482360B2Jan 27, 2009

Fused tetracyclic mGluR1 antagonists as therapeutic agents

SCHERING CORP15 citations84
US7368562B2May 6, 2008

Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

SCHERING CORP10 citations84
US7235543B2Jun 26, 2007

Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

SCHERING CORP13 citations84
US7109207B2Sep 19, 2006

Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

SCHERING CORP13 citations83
US6593078B1Jul 15, 2003

Use of azetidinone compounds

SCHERING CORP11 citations80
US7459442B2Dec 2, 2008

Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

SCHERING CORP3 citations63
US7192944B2Mar 20, 2007

Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

SCHERING CORP4 citations63
US7030113B2Apr 18, 2006

Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

SCHERING CORP2 citations62
US7598259B2Oct 6, 2009

mGluR1 antagonists as therapeutic agents

SCHERING CORP2 citations61
US7214691B2May 8, 2007

2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

SCHERING CORP6 citations61
US7144696B2Dec 5, 2006

Use of azetidinone compounds

SCHERING CORP1 citations60
US6933107B2Aug 23, 2005

Use of azetidinone compounds

SCHERING CORP1 citations60
US7902157B2Mar 8, 2011

Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism

SCHERING CORP1 citations52
US7741289B2Jun 22, 2010

Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

SCHERING CORP0 citations52
US7732413B2Jun 8, 2010

Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

SCHERING CORP0 citations52
US7378518B2May 27, 2008

Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

SCHERING CORP0 citations52
US7368563B2May 6, 2008

Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

SCHERING CORP0 citations52
US7211574B2May 1, 2007

Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders

SCHERING CORP1 citations52
US7687501B2Mar 30, 2010

Pyridothienopyridazinone derivatives as mGluR1 antagonists

SCHERING CORP2 citations51
US7504391B2Mar 17, 2009

Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders

SCHERING CORP1 citations51
US7989464B2Aug 2, 2011

mGluR1 antagonists as therapeutic agents

SCHERING CORP0 citations50
US7723020B2May 25, 2010

Use of azetidinone compounds

SCHERING CORP0 citations50
US7485648B2Feb 3, 2009

mGluR1 antagonists as therapeutic agents

SCHERING CORP1 citations50

WU WEN-LIAN

5 patents

MERCK SHARP & DOHME

3 patents

SCHERING PLOUGH CORP

2 patents

ASBEROM THEODROS

2 patents

AQUINNAH PHARMACEUTICALS INC

1 patent

SASIKUMAR THAVALAKULAMGARA K

1 patent

BURNETT DUANE A

1 patent

Showing the top 50 of 62 patents by PatentIndex Score.